Prostate Cancer
Conditions
Interventions
experimental group:neoadjuvant endocrine therapy combined with chemotherapy
control group:Nil
Sponsors
Department of Urology, Shanghai Changhai Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Male, life expectancy = 5 years; 2. Primary patients with prostate cancer confirmed by biopsy before enrollment; 3. Patients with high risk (PSA>20ng/ml or clinical stage = T2c or GS score = 8) assessed by magnetic resonance imaging (MRI) and whole body bone scanning (ECT); 4. Patients without prostate related surgery, radiotherapy and endocrine therapy; 5. Willing to truthfully fill in the subject survey scale; 6. Willing to accept long-term follow-up; 7. The patient himself or his authorized lineal relatives have signed the informed consent form for clinical trial.
Exclusion criteria
Exclusion criteria: 1. Patients with bone metastasis (M1b) assessed by whole body bone scanning (ECT); 2. Complicated with other malignant tumors; 3. Those who have undergone pelvic surgery in the past, but not including transurethral endovascular surgery; 4. Have received pelvic radiotherapy in the past; 5. Have received systematic chemotherapy or endocrine therapy in the past; 6. Patients with severe systemic diseases (cardiovascular and cerebrovascular diseases, etc.) can not tolerate surgery or radiotherapy; 7. Patients participating in other clinical trials at the same time; 8. Poor compliance, unable to follow up as planned.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| prostate specific antigen;free prostate specific antigen; | — |
Secondary
| Measure | Time frame |
|---|---|
| Testosterone;incontinence; | — |
Countries
China
Contacts
Public ContactXu Gao
Shanghai Changhai Hospital
Outcome results
None listed